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LETTER
Regulation of Illegal Drugs – No Longer “What”?, 
but “How”?
Brian Emerson
British Columbia Ministry of Health, CA
brian.emerson@gov.bc.ca
The debate about the prohibition of drugs has taken a fundamental turn with the publication 
of ‘Regulation: The Responsible Control of Drugs’ by the Global Commission on Drug Policy. 
This edition of the journal publishes papers addressing how to regulate drugs, which informed 
the Global Commission report. These papers shift the discussion from what must be done, i.e. 
end prohibition, to how regulation can be implemented. These papers shift the discourse from 
a ‘drugs are the problem’ paradigm to ‘management of drugs is the problem’. Implications of 
regulation means:
•	accepting that people should have controlled access, within a public health framework, to a 
range of psychoactive substances for non-medical use purposes 
•	highlighting of the incoherence of substance use management policy and regulation between 
legal and illegal substances
•	blurring the dichotomy concept of medical and non-medical use
•	supporting rigorous monitoring, evaluation, and research 
Consideration of implementing public interest–based regulated drug markets is gaining traction. 
This	will	not	be	without	challenges,	including	pressure	from	profit-driven	interests	to	weaken	
the public health orientation. Governments can be capable and competent when provided with 
technical support to regulate risky products, so should move from rigid adherence to the failed 
drug prohibition policy to regulation based on public health and human rights principles. This 
will help refocus on achieving the fundamental aim of the UN drug treaties – promotion of the 
health and welfare of humankind.
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The debate about the international prohibition of drugs, which restricts use for medical or scientific 
purposes only, has taken a fundamental turn with the publication of ‘Regulation: The Responsible Control 
of Drugs’ (Global Commission on Drug Policy 2018). Most of the debate to date, with exceptions (e.g. Rolles 
2009; Rolles & Murkin 2013; Haden, Emerson & Tupper 2016; Haden & Emerson 2014; Haden 2008), has 
been whether or not prohibition should be maintained, rather than how alternatives to prohibition should 
be implemented. Cannabis legalization in Uruguay, Canada and a number of US states has broached the 
implementation discussion, and now the Global Commission has provided clear guidance on how to end 
prohibition of all drugs through regulation. 
This edition of the journal publishes papers addressing how to regulate drugs, which informed the Global 
Commission report. 
The paper by Ben Lakhdar describes regulation tools, such as state monopoly wholesale and retail 
distribution based on the experience of government-owned alcohol monopolies, which he points out are 
considered more successful than private institutions in ensuring public health through such measures as 
price controls, advertising bans, health warnings, child-resistant packaging, licensing and public interest–
oriented governance boards.
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The paper by Schneider addresses how regulating drug markets may help better control organ-
ized crime. He assesses the limitations of regulation on organized crime and mentions challenges such 
as dealing with popular support for drug trafficking organizations due to their links to a labor-inten-
sive illegal economy, developing alternative sources of income and support for economically neglected 
regions and reforming and re-directing law enforcement to more effectively deal with drug trafficking 
organizations. 
Jelsma and Walsh point out that ignoring or denying that regulation of cannabis and coca contravene UN 
drug control treaties obligations is ‘untenable and risks undermining basic principles of international law’. 
Their view is that revising or amending the treaties to accommodate regulation is not feasible and that the 
most legitimate approach is ‘elaborating a new agreement among like-minded countries on the basis of the 
inter se procedure for treaty modification, as provided by Article 41 of the Vienna Convention on the Law 
of Treaties’. 
Snapp, Tinasti, and Herrara describe the challenges of regulation in developing economies with fragile 
or corruption-sensitive institutions and the importance of a social justice perspective. They highlight the 
risks of corruption and diversion, point out best practice examples to mitigate these risks and for enhancing 
social justice, remind us that prohibition has not been successfully implemented in fragile or well developed 
states, and that all ‘Governments know how to regulate risky products’.
These papers continue to shift the discussion from what must be done, i.e. end prohibition, to how 
regulation as an alternative to prohibition can be implemented. By describing details, challenges, poten-
tial unintended effects, and successes of regulation these papers shift the discourse from a ‘drugs are the 
problem’ paradigm to the paradigm that ‘management of drugs is the problem’. In reality, all drugs are sim-
ply plants, plant extracts, or synthetic substances, which do not possess an inherent malevolent nature, i.e. 
they are not evil, as intimated by the UN Single Convention (Anonymous, 1972).
A common observation of these papers is that there is much to be learned from the management, and 
mismanagement, of alcohol, tobacco, pharmaceuticals, gambling, and even coffee that could be applied 
to regulating currently illegal drugs. The flip side is that the lessons about the mismanagement of 
tobacco, alcohol, and pharmaceuticals could be applied to improve regulation of these legal substances 
as well.
While these papers and the Global Commission report provide helpful ideas about how to implement 
regulation, the implications are also important to consider.
In particular, regulation means accepting that people should have controlled access, within a public 
health framework, to a range of psychoactive substances such as opioids, stimulants, and psychedelics 
for non-medical use purposes. This may sound radical given the strict limitations of the UN Treaties to 
use drugs only for medical and scientific purposes, but is in fact an outcome of the legalization of 
cannabis. 
A second implication is the highlighting of the incoherence of substance use management policy and 
regulation between legal and illegal substances, and the importance of managing all substances from a 
public health and human rights perspective. Attention to policy coherence across substances leads policy 
makers to learn from the profit-driven commercialization and promotion mismanagement of tobacco and 
alcohol, which has been to the detriment of hundreds of millions of people (Global Burden of Disease, 
2018). Profit-driven commercialization and promotion mismanagement of pharmaceutical opioids is 
also part the cause of the current opioid overdose epidemic in North America (Kolodny et al. 2015; 
Global Commission on Drug Policy 2017). These lessons are important to inform plans to regulate illegal 
drugs. 
A third implication of regulating drugs will be blurring the dichotomy concept of medical and non-medical 
use. Given that people use substances for a wide range of purposes (Muller & Schumann 2011), recogniz-
ing this reality will raise critical questions: Should there be other gatekeepers to drugs beyond doctors and 
pharmacists, and if so, who should they be? What should be their training? How should they be regulated? 
Should there be public insurance coverage for a broader range of substances? What are the implications for 
the current medical/pharmacist prescription control of drugs system? These are very challenging issues to 
be addressed, but recognizing this false dichotomy will lead to more reality-based policies.
Fourthly, given that re-regulation of currently prohibited substances has not been done until recently, in 
a limited way with cannabis, and that such a shift in policy will be done based on expert opinion and other 
rationale rather than direct evidence, it will be critical that governments commit to supporting rigorous 
monitoring, evaluation, and research and anticipate being flexible to change course should unintended 
negative consequences emerge.
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If successful, regulation may demonstrate the following:
•	 Out-competing, rather than waging war, on the illegal market is a more productive, efficient, and 
humane approach.
•	 One-size-fits-all approaches are more harmful than helpful.
•	 Pragmatism rather than ideology is a more useful guiding principle.
•	 Most people are capable of safe self-management of their use of drugs, and for the minority who 
develop use problems, help should be readily available.
•	 A socio-medical model is more productive than a strict medical model.
•	 Regulation is harm reduction on a grand scale.
•	 Regulation can free up police and other criminal justice system resources.
•	 People, not drugs need to be the focus.
•	 Setting clear goals and objectives and measuring progress is important.
•	 Reparations for people harmed by the “war on drugs” are warranted. 
In conclusion, consideration of how to replace profit-driven illegal and commercial drug markets with public 
interest–based regulated markets, known as a public health approach (Emerson & Haden 2017) is gaining 
traction. However, this shift will not be without significant challenges, including continuous pressure from 
profit-driven interests to weaken the public health orientation. Experience with regulating cannabis and 
coca can generate knowledge that can be applied to the more complicated efforts of regulating more harm-
ful substances, such as heroin, synthetic opioids, and amphetamines. Because governments can be capable 
and competent when provided with technical support to regulate risky products, it behooves them to move 
from rigid adherence to the failed drug prohibition policy to regulation based on public health and human 
rights principles. This will refocus on achieving the fundamental aim of the UN drug treaties – promotion of 
the health and welfare of humankind.
‘This approach is neither one of total abdication nor an indication of abandonment but rather a 
vision of the role of the State and criminal law as developing and promoting but not controlling 
human action, and as stipulating only necessary prohibitions relating to the fundamental principle 
of respect for life, other persons, and harmonious community, and as supporting and assisting 
others, not judging and condemning difference.’ 
Senator Pierre Claude Nolin (Nolin 2002: 617)
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